Outlook for 2022

Oriola Corporation published a new outlook for 2022 after finalising the combining of Oriola’s Kronans Apotek and Euroapotheca’s Apoteksgruppen into a new jointly owned company.

The new outlook for 2022 (published on 3 October 2022)

The adjusted EBIT for the continuing operations is estimated to increase from the 2021 level. The new outlook is based on Oriola’s continuing operations.

The COVID-19 pandemic continues and severity as well as duration of the pandemic remain unclear in Oriola’s operating environment. Furthermore, the recent overall inflationary increases and related cost pressures may have a significant impact on Oriola’s profitability.

The comparable adjusted EBIT in 2021 was EUR 14.9 million for the continuing operations.

The previous outlook for 2022 (published on 18 February 2022)

The comparable adjusted EBIT is estimated to increase from the 2021 level.

The COVID-19 pandemic continues and severity as well as duration of the pandemic remain unclear in Oriola’s operating environment. Furthermore, the recent overall inflationary increases and related cost pressures may have a significant impact on Oriola’s profitability.

The outlook remains based on current group structure, including both continuing operations and discontinued operations. The comparable adjusted EBIT in 2021 was EUR 26.3 million.